Business Wire

CSC Global Financial Markets Acquires FIRSTCORP PTE. LTD in Singapore

Share

CSC, a world leader in global business, legal, tax, and digital brand services, is pleased to announce that it has acquired FIRSTCORP PTE. LTD (FIRSTCORP) and its affiliates, a Singapore-based service provider of company secretary and administration services to corporations and alternative asset managers.

FIRSTCORP offers company formation, corporate secretarial, and domiciliation services. It specializes in the establishment and ongoing administration of Singapore companies as well as business entities in other key financial centers including Hong Kong, and other jurisdictions such as the British Virgin Islands, Cayman Islands, and Labuan. By managing the administrative and corporate secretarial compliance responsibilities of businesses operating in those jurisdictions—together with its strong network of partners—FIRSTCORP’s services enable its clients to navigate the increasingly complex international regulatory environment.

“We’re delighted to welcome FIRSTCORP to CSC, as the move strengthens our service offering in the Asia-Pacific market,” says CSC Executive Vice President John Hebert. “FIRSTCORP has an impressive track record and strong service-oriented culture similar to our own. Its jurisdictional expertise, bespoke solutions, and long-term approach to managing client relationships make it an excellent addition to our overall global offering.”

The acquisition of this Singapore-based business extends CSC’s capabilities for its Global Financial Markets (GFM) clients and boosts its physical presence in a leading Asia-Pacific (APAC) financial center. CSC already has an established team in Singapore, as well as additional APAC locations in Hong Kong, Shanghai, and Shenzhen. The acquisition follows several strategic hires and investments CSC has made in APAC in the last year, including scaling its fund administration offering and bolstering its international expansion businesses in the region. This has enabled CSC to provide administration services for corporations, family offices, and fund structures, such as Singapore variable capital companies (VCC), in addition to multiple structures related to venture capital, private equity, real estate, and trade finance and loan administration funds.

“Beyond extending our capabilities in APAC, this acquisition complements the market, regulatory, and jurisdictional expertise we provide to clients to help them achieve their business objectives,” says Agnes Chen, managing director of CSC’s APAC region. “Our ability to provide a wide range of support, from initial fund setup and onboarding to day-to-day administration of funds and investment structures and corporate services, is highly valued by clients and makes for a strong cultural fit between our respective organizations.”

FIRSTCORP was founded in 2003 and is centrally located in the heart of the Singapore business and financial district. All FIRSTCORP employees will join CSC as part of the acquisition.

“By joining forces with CSC, we’re reinforcing our local expertise with CSC’s global capabilities,” says FIRSTCORP Director Jenny Oh. “We share CSC’s vision of becoming the leading corporate service provider in our industry. And by joining together, we will be able to offer more services to our local clients, as well as expand our offerings to clients in North America, Europe, and the Asia Pacific Region.”

About CSC

CSC is a leading provider of specialized administration services to alternative asset managers across a range of fund strategies, capital markets participants in both public and private markets, and corporations requiring fiduciary and governance support. We are the unwavering partner for 90% of the Fortune 500®, nearly 10,000 law firms, and more than 3,000 financial institutions. CSC’s Global Financial Markets professionals are located in key financial centers across the U.S., Europe, and Asia-Pacific. We are a global company capable of conducting transactions wherever our clients are―and we accomplish that by deploying experts in every business we serve. For more information about CSC's services, visit cscgfm.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Laura Crozier
Public Relations Manager
(302) 636 5401 x. 65526
CSC News Room

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 10:00:00 EET | Press release

With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global international showcase for food innovation, allowing brands and companies to ex

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye